6.2 Red Cell Antibody Screening, Identification Panels, and Dosage Effects

6.2 Red Cell Antibody Screening, Identification Panels, and Dosage Effects

Unexpected Antibody Screening

The antibody screen is a cornerstone of pretransfusion compatibility testing. While ABO testing detects naturally occurring antibodies, the screen targets unexpected, clinically significant alloantibodies generated from previous transfusions or pregnancies. The test employs 2 or 3 Group O screening cells. Group O is utilized to prevent interference from the patient's ABO antibodies (Anti-A, Anti-B).

The screening cells are meticulously phenotyped to ensure representation of all major clinically significant antigens: D, C, E, c, e, K, k, Fya, Fyb, Jka, Jkb, Lea, Leb, P1, M, N, S, and s.

Phases of Testing

Antibody screening and identification are conducted across multiple phases to isolate specific classes of immunoglobulins based on their optimal thermal amplitude:

1. Immediate Spin (IS): Patient serum and reagent cells are mixed and centrifuged at room temperature. This phase identifies cold-reacting IgM antibodies (e.g., Anti-M, Anti-N, Anti-P1, Anti-Lea, Anti-Leb). These are typically clinically insignificant unless they react at 37°C.
2. 37°C Incubation: Promotes the binding of warm-reacting IgG antibodies. Potentiators are frequently added to enhance reactivity and reduce incubation time:
   • LISS (Low Ionic Strength Saline): Decreases the zeta potential surrounding red cells, allowing antibodies to attach more rapidly.
   • PEG (Polyethylene Glycol): Removes water molecules, forcing antibodies and red cells into closer proximity. PEG is excellent for enhancing weak Rh and Kidd antibodies but requires skipping the 37°C macroscopic read to avoid false positives.
3. Antiglobulin (AHG) Phase: Following washing, Anti-Human Globulin is added. AHG bridges the gap between IgG-sensitized red cells, facilitating visible lattice formation (agglutination). This phase detects potent, clinically significant IgG antibodies such as Anti-D, Anti-K, Anti-Jka, and Anti-Fya.

Antibody Identification Panels

When a screening test is positive, an antibody identification panel is deployed. The panel utilizes 10 to 20 Group O reagent red cell suspensions, accompanied by an extensive lot-specific master list (antigram) detailing the exact antigen makeup of each cell.

Panel Resolution and the "Rule-Out" Method

Interpreting a panel involves systematic deductive reasoning:

1. The Autocontrol: The patient's serum is tested against their own red cells. A positive autocontrol suggests an autoantibody or a recent transfusion leading to a delayed hemolytic reaction. A negative autocontrol confirms the presence of an alloantibody.
2. Ruling Out (Crossing Out): Analysts evaluate panel cells that yielded completely negative (0) reactions across all phases. If a panel cell did not react with the patient's serum, the patient most likely does not have an antibody against any antigen present on that specific cell. Those antigens are "ruled out" by crossing them off the master list.
3. The Rule of Three: To statistically confirm the identity of an antibody and ensure it is not a random occurrence, the reaction pattern must meet the Rule of Three. This requires at least 3 panel cells positive for the suspected antigen that react with the serum, and at least 3 panel cells negative for the antigen that do not react. This achieves a statistical confidence interval (p-value) of 0.05.

The Dosage Effect

A critical concept in immunohematology is dosage. Certain antibodies react more vigorously with red cells possessing a double dose (homozygous expression) of the target antigen compared to cells with a single dose (heterozygous expression).

• Homozygous: e.g., Jk(a+b-) means the cell has a double dose of Jka.
• Heterozygous: e.g., Jk(a+b+) means the cell has a single dose of Jka and a single dose of Jkb.

When ruling out antibodies known to exhibit dosage, the analyst must use homozygous cells. If a heterozygous cell is used for rule-out, a weak antibody might falsely appear negative, leading to an incorrect conclusion.

• Blood Groups Exhibiting Significant Dosage: Kidd (Jka/Jkb), Duffy (Fya/Fyb), MNS (M/N, S/s), and Rh (C/c, E/e).

Proteolytic Enzyme Treatment Effects

When multiple antibodies are present, sorting them out can be challenging. Proteolytic enzymes like ficin (from figs) and papain (from papaya) modify the red cell membrane by cleaving sialic acid glycoproteins. This eliminates some antigens while exposing and enhancing others.

• Antigens Destroyed: M, N, S, s, and Duffy (Fya, Fyb). If a serum contains Anti-Fya and Anti-K, running the panel with enzyme-treated cells will destroy the Fya antigen, causing the Anti-Fya to stop reacting, leaving only the Anti-K visible.
• Antigens Enhanced: Rh (D, C, c, E, e), Kidd (Jka, Jkb), Lewis (Lea, Leb), I, and P1. Kidd antibodies, which notoriously cause delayed hemolytic transfusion reactions, are drastically enhanced by enzymes.
• Antigens Unaffected: Kell (K, k).

Exam Trap: A classic memory aid is "Destroyed by enzymes: M, N, S, s, and Duffy". Understanding which antigens survive enzyme treatment is a heavily tested competency in resolving complex mixtures.